PIK3CA

Laboratory assay overview

This test is intended to be used as a disease specific solid tumor panel to aid the oncologist in prioritizing standard of care therapy choices for their patients with Colorectal Cancer.

Laboratory assay overview

This test is intended to be used as a disease specific solid tumor panel to aid the oncologist in prioritizing standard of care therapy choices for their patients with Colorectal Cancer.

Laboratory assay overview

This test is intended to be used for the molecular genotyping of tumors from patients with Non-Small-Cell Lung Cancer in order to help prioritize treatment.

Laboratory assay overview

Disease-specific solid tumor panel intended to aid the oncologist in prioritizing standard of care therapy and clinical trial choices for patients with advanced stage melanoma.

Laboratory assay overview

Solid Tumor Genomics from Quest Advanced Diagnostics - Precision medicine is an emerging approach for disease prevention and treatment that takes individual variability into account. This next-generation sequencing (NGS) panel along with the computational resources and tools that process and analyze the data, allows the characterization of individual patients and tumor types. Guidelines exist for using results from many of these genes for selection of FDA approved therapies. This NGS panel can accurately and sensitively sequence more target genes with less DNA, with reduced cost, time and labor as compared with more limited sequencing methods and the physician can become aware of alternative treatments available to the patient based on presence of mutations in other genes the physicians might not have considered. Microsatellite instability (MSI) and tumor mutation burden (TMB) are also included. The panel allows the generation of diverse data obtained and analyzed in real-time, enabling enrollment in specific clinical trials, and adaptation of treatment strategies.